Advertisement


Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Advertisement